Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397803 | 0.85 | CA2 (0.47) | CA2SLC6A4HTR2APOLBHSP90AA1 | |
| SCHEMBL15055216 | 0.83 | CA2 (0.59) | CA2POLBKDM4EALDH1A1LMNA | |
| SCHEMBL1029174 | 0.82 | SLC6A4 (0.54) | CA2SLC6A4HTR2APOLBHSP90AA1 | |
| SCHEMBL3392851 | 0.82 | CA2 (0.52) | CA2POLBKDM4EALDH1A1LMNA | |
| SCHEMBL15471928 | 0.81 | CA2 (0.41) | CA2POLBHSP90AA1ALDH1A1PIK3CA | |
| Hydrochloric Acid SCHEMBL5385069 | 0.81 | CA2 (0.50) | CA2POLBKDM4EALDH1A1LMNA | |
| SCHEMBL6684335 | 0.79 | CA2 (0.53) | CA2 | |
| SCHEMBL31480988 | 0.78 | CA2 (0.47) | CA2SLC6A4HTR2APOLBKDM4E | |
| SCHEMBL3395940 | 0.78 | CA2 (0.47) | CA2SLC6A4HTR2APOLBKDM4E | |
| SCHEMBL19641588 | 0.78 | CA2 (0.47) | CA2POLBKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-03 | — | — | US | claimed |
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PFIZER INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-03 | — | — | US | disclosed |
| EP-2245011-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009090173-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346567-A1 | SUBSTITUTED PYRIDINE AND PHENYL COMPOUNDS | PAH, PC, MPC2 | CA2 3780/4885SLC6A4 357/4885HTR2A 3438/4885 |
| US-20110053985-A1 | NOVEL PIPERIDINE-4-CARBOXYLIC ACID PHENYL-ALKYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | CA2 2007/4885SLC6A4 4/4885HTR2A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.